Fri, August 23, 2024
[ 12:00 AM ] - WOPRAI
Thu, August 22, 2024
[ 12:00 AM ] - WOPRAI
Wed, July 17, 2024
[ 12:00 AM ] - WOPRAI
Wed, June 26, 2024
[ 12:00 AM ] - WOPRAI
Wed, June 5, 2024
[ 12:00 AM ] - WOPRAI
Mon, June 3, 2024
[ 12:00 AM ] - WOPRAI
Tue, May 28, 2024
[ 12:00 AM ] - WOPRAI
Wed, May 15, 2024
[ 12:00 AM ] - WOPRAI
Fri, May 10, 2024
[ 12:00 AM ] - WOPRAI
Fri, May 3, 2024
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Thu, April 4, 2024
[ 12:00 AM ] - WOPRAI
Fri, March 1, 2024
[ 12:00 AM ] - WOPRAI
Fri, February 16, 2024
[ 12:00 AM ] - WOPRAI
Thu, February 15, 2024
[ 12:00 AM ] - WOPRAI
Fri, February 9, 2024
Wed, August 16, 2023
Fri, August 11, 2023
[ 12:00 AM ] - WOPRAI
Tue, August 8, 2023
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Fri, August 4, 2023
[ 12:00 AM ] - WOPRAI
Thu, June 22, 2023
[ 12:00 AM ] - WOPRAI
Tue, June 6, 2023
[ 12:00 AM ] - WOPRAI
Fri, June 2, 2023
[ 12:00 AM ] - WOPRAI
Wed, May 24, 2023
[ 12:00 AM ] - WOPRAI
Thu, May 11, 2023
Wed, April 19, 2023
Thu, March 30, 2023
[ 12:00 AM ] - WOPRAI
Fri, March 3, 2023
[ 12:00 AM ] - WOPRAI
Fri, February 24, 2023
Keay Nakae Maintained (SONN) at Strong Buy and Held Target at $240 on, Aug 23rd, 2024
Keay Nakae of Chardan Capital, Maintained "Sonnet BioTherapeutics Holdings, Inc." (SONN) at Strong Buy and Held Target at $240 on, Aug 23rd, 2024.
Keay has made no other calls on SONN in the last 4 months.
There is 1 other peer that has a rating on SONN. Out of the 1 peers that are also analyzing SONN, 0 agree with Keay's Rating of Hold.
This is the rating of the analyst that currently disagrees with Keay
- Tim Moore of "EF Hutton" Maintained at Strong Buy with Decreased Target to $56 on, Thursday, May 16th, 2024
Contributing Sources